Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression.

Dipartimento di Salute Mentale, Università degli Studi di Torino, Orbassano, Torino, Torino, Italy.
International Clinical Psychopharmacology (Impact Factor: 3.1). 07/2004; 19(4):191-9. DOI: 10.1097/01.yic.0000117902.43995.b0
Source: PubMed

ABSTRACT Erectile dysfunction (ED) and depression are highly prevalent and frequently comorbid. Sildenafil effectively treats ED in men with depression and in men taking antidepressants. We evaluated the efficacy of sildenafil in men with depression in remission and ED. Patients with a history of ED when major depressive disorder (MDD) was diagnosed, which persisted after MDD was treated to remission, were randomized to 12 weeks of treatment with sildenafil (50 mg, flexible) or placebo. Efficacy was assessed using intercourse success rates, a global efficacy question (Has treatment improved your erections?), the International Index of Erectile Function (IIEF) and Life Satisfaction Checklist (LSC). By week 12, intercourse success rates were significantly higher among sildenafil- (74%) compared to placebo-treated patients (29%; P=0.0001). About 83% and 34% of sildenafil- and placebo-treated patients, respectively, reported improved erections (odds ratio=9.4, P=0.0001). IIEF scores in the sildenafil group (n=83) were significantly improved compared to those in the placebo group (n=85; P <0.0001). LSC sexual life item improved significantly among sildenafil- versus placebo-treated patients. The most frequently reported adverse events were transient and mild-to-moderate. Sildenafil is an effective and well-tolerated treatment for ED in patients with a history of ED at the time of MDD diagnosis, and which persisted after the MDD was treated to remission.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Is a vaginal preparation of sildenafil citrate capable of alleviating acute menstrual pain in patients with primary dysmenorrhea (PD)? A vaginal preparation of sildenafil citrate is capable of alleviating acute menstrual pain in patients with PD with no observed adverse effects. Oral preparations of nitric oxide (NO) donor drugs augment relaxant effects of NO on myometrial cells, reverse the vasoconstriction caused by prostaglandins and successfully alleviate pain, but the incidence of side effects is too high for routine clinical use. Sildenafil citrate inhibits type 5-specific phosphodiesterase (PDE5), thus preventing the degradation of cyclic guanosine monophosphate (cGMP) in the muscle and augmenting the vasodilatory effects of NO. Therefore, by inhibiting PDE5, the tissue remains relaxed and more blood can circulate through. It has been used previously in a vaginal form with no observed side effects, and it enhances endometrial blood flow. A double-blind, randomized, controlled trial comparing vaginal preparation of sildenafil citrate (100 mg single dose) to a placebo in 62 PD patients at the time of painful menstruation was conducted. The primary outcome was total pain relief over 4 consecutive hours (TOPAR4) comparing sildenafil citrate to placebo, where higher TOPAR4 scores represent better pain relief. Secondary outcomes were pain relief as measured by the visual analog scale (VAS) and uterine artery pulsatility index (PI). Subjects were recruited from December 2007 to January 2011. The trial was stopped due to closeout of the funding for the study. Participants were women in good health, were aged 18-35 years and suffered from moderate to severe PD. They were randomized to either vaginal placebo or 100 mg vaginal sildenafil citrate in a 1:1 ratio using random permuted blocks having a block size of 4. At baseline and 1, 2, 3, and 4 h post-treatment, patients were asked to provide assessment of their degree of pain using two scales: (i) pain on the 5-level ordinal scale used for TOPAR4 calculation and (ii) pain level on the VAS. The study ended 4 h after treatment initiation. Twenty-five subjects completed the study. Using the TOPAR4 score, the sildenafil citrate group had significantly better pain relief compared with the placebo group [mean (SD): 11.9 (3.2) versus 6.4 (2.1), respectively; difference in means = 5.3; 95% CI: (2.9,7.6); P < 0.001)]. On the VAS, sildenafil citrate provided better pain relief than placebo at each time point. At the 2-h time point, the PI was significantly lower in the sildenafil citrate group compared with the placebo group [mean (SD): 1.6 (0.6) versus 2.3 (0.5), respectively; difference in means = -0.7; 95% CI: (-1.2, -0.1); P = 0.01)]. Since we did not meet our sample size due to the loss of funding and could not confirm our primary hypothesis, larger studies of longer duration, likely multi-center, are needed to confirm the findings from this study. A number of medications have been investigated to improve the treatment options for PD, but most have proven unsuccessful or to have an unfavorable risk/benefit ratio. Since PD is a condition that most women suffer from and seek treatment for at some point in their lives, our study offers hope that vaginal sildenafil citrate is a safe and effective option for patients who do not desire or are unresponsive to treatments now available on the market. Funding for this study was provided by National Institutes of Health (NIH) grants RO3 TW007438 and K24 HD01476. The authors report no relevant conflicts of interest. NCT00123162 (Clinical
    Human Reproduction 08/2013; DOI:10.1093/humrep/det324 · 4.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Male Wistar Albino mice were co-administrated with appropriate dose of sildenafil citrate and alcohol. The kidney samples of those animals were analyzed for lipid peroxidation and antioxidant contents. Lipid peroxidation was measured based on TBARS. Antioxidant such as SOD, CAT, GPx and GSH were also determined. From the present investigation, an enhanced level of TBARS accompanied by a decreased concentration of enzymic as well as non-enzymic antioxidants in kidney was detected for 30 days animals treated concomitantly with sildenafil citrate and alcohol. Increased level of lipid peroxidation lead to accumulation of free radicals and increased oxidative threat in kidney tissues. Also, the decreased concentration of antioxidant enzymes in renal tissues indicates the failure of antioxidant defence system.
    Spectroscopy 01/2011; 26(4-5). DOI:10.3233/SPE-2011-0541 · 0.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nonlinear optics is essential to the development of lidar and DIAL wavelengths. Harmonic generation is used to generate widely spaced wavelengths needed for atmospheric component measurement. Seeding is accomplished by using the idler from a LiNbO3 parametric oscillator pumped by Nd:YAG laser.
    Conference Proceedings - Lasers and Electro-Optics Society Annual Meeting-LEOS 01/2003; 2. DOI:10.1109/LEOS.2003.1253112